The Primatene Mist inhaler is the only over-the-counter (OTC) asthma inhaler approved by the FDA for the relief of asthma ...
Amphastar's Q2 2024 revenue grew 25% year-over-year to $182.4 million, primarily driven by BAQSIMI and Primatene MIST sales. Primatene MIST faces future challenges as its key patent expires in ...